Project Toxicology and Ion Channel Screening for Redx Pharma

Redx Pharma is a drug discovery and development company focused on creating new drugs for areas such as cancer and immunology. Redx recognised a need for expert safety input and ion channel screening data to develop high quality clinical candidates.
Through this relationship, Redx had access to the entire team of nonclinical safety experts. Our experts worked closely with Redx scientists, to provide guidance on nonclinical safety and DMPK strategy, as well as gap analysis, data interpretation and advice on next steps. For the lead programs entering GLP toxicity studies, we worked with Redx to influence study design and decision-making, as well as data interpretation. We co-authored the submission documents and participated in regulatory agency interactions.
In this extremely successful partnership, we have developed a model relationship with Redx Pharma. For the two most advanced projects, one was successfully divested to a US biotech, and the other achieved a successful CTA.